The drug has been developed by DRDO’s Institute of Nuclear Drugs and Allied Sciences (INMAS) in collaboration with Dr Reddy’s Laboratories.
DRDO Chairman Dr G Satheesh Reddy stated that DRDO and Dr Reddy’s lab had gone by way of the whole trials and performed trials throughout 30 hospitals and on numerous sufferers.
The primary batch of 10,000 doses of 2-DG medication could be launched early subsequent week, knowledgeable DRDO officers to ANI on Friday.
The drug is available in powder type in a sachet, which is taken orally by dissolving it in water. It accumulates within the virus-infected cells and prevents virus development by stopping viral synthesis and power manufacturing. Its selective accumulation in virally contaminated cells makes this drug distinctive.
Within the ongoing second Covid-19 wave, numerous sufferers are dealing with extreme oxygen dependency and wish hospitalisation. The drug is anticipated to save lots of treasured lives as a result of mechanism of operation of the drug in contaminated cells. This additionally reduces the hospital keep of Covid-19 sufferers.